SNPMiner Trials (Home Page)
Report for Mutation C825T
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents
The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).
NCT01670396 Coronary Artery Disease MeSH:Coronary Artery Disease
HPO:Coronary artery atherosclerosis
The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins. --- C825T ---
Primary Outcomes
Measure: In-stent restenosis Time: 6-24months after stent implantingSecondary Outcomes
Measure: target lesion revascularization (TLR) Time: 6-24months after stent implantingMeasure: re-myocardial infarction Time: 6-24months after stent implating
2 Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans
The response to therapy with a fixed dose combination of isosorbide dinitrate and hydralazine (FDC I/H) is enhanced in African Americans with heart failure and reduced ejection fraction (HFrEF) when compared to similar white cohorts. This study will seek to confirm the previous genetic sub-study from AHeFT which suggested a functional polymorphism of guanine nucleotide binding protein beta polypeptide 3 subunit (GNB3), C825T in exon 10, influences the therapeutic efficacy of FDC I/H. This study will initiate treatment with FDC I/H in 500 self designated African American subjects with systolic heart failure. They will be followed for up to two years on therapy. Clinical outcomes (survival, heart failure hospitalizations, and change in quality of life) on FDC I/H will be compared by GNB3 genotype subset. The hypothesis to be confirmed is that subjects homozygous for the T allele (those with the GNB3 TT genotype which is present in approximately 50% of black subjects) demonstrate enhanced therapeutic benefit from FDC I/H.
NCT02305095 Heart Failure Drug: FDC I/H MeSH:Heart Failure
HPO:Congestive heart failure Left ventricular dysfunction Right ventricular failure
This study will seek to confirm the previous genetic sub-study from AHeFT which suggested a functional polymorphism of guanine nucleotide binding protein beta polypeptide 3 subunit (GNB3), C825T in exon 10, influences the therapeutic efficacy of FDC I/H. --- C825T ---
Primary Outcomes
Description: The CS combines three outcome variables into a single "score". Composite score adds points for survival over 2 years of follow up (death at any time yields -3 points, survival to end of study results in 0), heart failure hospitalization over 2 years of follow up (yes at any time results in -1 point, no results in 0), and the change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire from entry to 6 months (change of ten units or greater=increase +2, decrease-2; change 5 to 9= increase+1, decrease -1; change < 5 units for the raw score yields 0 points). The CS will range from -6 to +2 for each patient.
Measure: Composite score (CS) no units. (survival, heart failure hospitalization, and change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire) Time: 2 yearsSecondary Outcomes
Description: Comparison of survival on therapy by GNB3 genotype
Measure: Survival Time: 2 yearsDescription: Comparison of event free survival by GNB3 genotype.
Measure: Survival free from heart failure hospitalization Time: 2 yearsDescription: Evaluate the change in the raw score of the Quality of Life questionnaire by GNB3 genotype.
Measure: Change in Quality of Life Assessment by Minnesota Living with Heart Failure Questionnaire Time: 6 months